Downloads

LIDE has one of the largest biobanks in the world due to the fresh patient samples collected daily from our hospital network. We have over 1600 PDX models and 100 human cancer cell lines, both of which contain rare mutations and drug resistance.

Download

MiniPDX® is an in-vivo version of a 3D organoid, and a faster alternative to PDX, without a lost in predictive power for drug response.

Download

LIDE has partnered with several pharma and biotech companies on preclinical efficacy evaluation projects of gene therapies.

Download

LIDE provides a one-stop solution with various immune-oncology platforms to support an all-around biologics R&D in immunotherapy.  We have also developed a unique human PBMC/cancer cell co-transfer model which can generate three-dimensional huPBMC-infiltrated tumor tissue for immunotherapy. 

Download

Using fresh patient samples received daily from our hospital network, LIDE has established 1600+ high quality PDX models in more than 40 cancer types, many with rare mutations or drug resistance.

Download

Imaging Mass Cytometry (IMC) is a relatively new technology and is an evolution of flow cytometry. IT uses metal-tagged antibodies (instead of fluorescence labeling) to enable high-throughput analysis and characterization of the tissue microenvironment, empowering researchers to investigate up to 35 markers simultaneously on a single section of tissue and up to 100 parameters in a single molecule (vs. about 18 max in traditional flow cytometry).

Download

LIDE has established brain metastatic patient-derived orthotropic xenografts (PDOXs) models, including metastasis from breast and gastric cancers.

Download

Our novel PDOX procedure converts hematological malignancies into an orthotopic model for robust efficacy studies. LIDE has established over 20 hematological malignancy patient-derived orthotropic xenografts (PDOXs) including AML, ALL, multiple myeloma, and different kinds of lymphoma.

Download